Raul R. Rodriguez - Nov 25, 2024 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Signature
/s/ Raymond Furey (Attorney-in-Fact)
Stock symbol
RIGL
Transactions as of
Nov 25, 2024
Transactions value $
$0
Form type
4
Date filed
11/26/2024, 08:01 PM
Previous filing
Sep 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +30K $0.00 30K Nov 25, 2024 Common Stock 30K $18.70 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted a stock option with a performance-based condition with respect to 30,000 shares of the Issuer's common stock on January 26, 2023, as adjusted for the one-for-ten reverse stock split effective June 27, 2024 (the "Reverse Stock Split"). The exercise price of this option is $18.70, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant, as adjusted for the Reverse Stock Split. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On November 25, 2024, it was determined that the performance metric had been met.
F2 The option was fully vested on November 25, 2024, the date the determination was made that the performance metric had been met.